Antibodies News and Research

RSS

Researchers in Japan compare two seroprevalence antibody tests for SARS-CoV-2

Researchers have shown that using reliable antibody tests in conjunction is an effective way to estimate seroprevalence in low prevalence settings.

1 Feb 2021

CDC examines COVID-19 outbreak among U.S. office workers: a case study in transmission

Researchers from the Centers for Disease Control and Prevention and the Federal Emergency Management Agency in the U.S. found that despite mitigation efforts, two COVID-19 outbreaks emerged among office workers in Washington, DC.

1 Feb 2021

New platform for detecting and monitoring SARS-CoV-2 antibody responses

Researchers in the U.S. have released a new study that describes a powerful but inexpensive tool designed to detect and monitor specific antibodies to SARS-CoV-2 over time.

1 Feb 2021

Inhaled single dose vaccine creates antibodies and prevents infection in rhesus macaques

Now, a new preprint research paper describes a chimpanzee adenovirus-vectored vaccine that, when administered intranasally in rhesus macaques, led to a robust immune response and demonstrated protection against infection by the virus that causes COVID-19, namely, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The preprint is published on the bioRxiv server.

1 Feb 2021

India's Covaxin vaccine likely effective against UK SARS-CoV-2 variant: Study

A new preprint research paper, posted to the preprint server bioRxiv, presents data indicating that the Indian-made Covaxin vaccine candidate successfully neutralizes this variant, preventing infection when challenged by it.

1 Feb 2021

SARS-CoV-2-specific T cells are key players in decreasing COVID-19 mortality

A recent US study, currently available on medRxiv preprint server, supports a beneficial rather than immunopathologic role for effector T-cells during serious infections with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) –

31 Jan 2021

Crystal structures of nanobodies could aid the design of COVID-19 therapies

Researchers at the National Institutes of Health in Bethesda, Maryland, have shown how certain synthetic nanobodies bind to the agent that causes coronavirus disease 2019 (COVID-19) – a development that could help inform the design of therapies.

31 Jan 2021

New COVID-19 test uses a smartphone microscope to quickly analyze saliva samples

Researchers at the University of Arizona are developing a COVID-19 testing method that uses a smartphone microscope to analyze saliva samples and deliver results in about 10 minutes.

29 Jan 2021

Researchers explore adaptive immunity against human coronaviruses

A recent study shows that long-term adaptive immunity to endemic coronaviruses is widespread, but low in magnitude, and that it shares phenotypic features of spike-specific antibodies and T cell memory across all tested coronaviruses.

29 Jan 2021

How feasible is at-home antibody testing for COVID-19?

Researchers at King’s College, London, have found that self-administered, at-home antibody testing could be a simple method for virus surveillance on university campuses.

29 Jan 2021

Researchers develop ‘next-generation vaccine platform’ against SARS-CoV-2

Researchers have designed a subunit vaccine based on the SARS-CoV-2 spike protein co-administered with CpG (Oligodeoxyribonucleotides) adjuvant.

29 Jan 2021

Scientists create new way to detect COVID-19 proteins and antibodies

Scientists have created a new way to detect the proteins that make up the pandemic coronavirus, as well as antibodies against it. They designed protein-based biosensors that glow when mixed with components of the virus or specific COVID-19 antibodies.

29 Jan 2021

Physicians receive Pfizer Prize for research on leukemia, cardiac arrhythmias

This year, four of a total of fifteen Pfizer Research Prizes have been awarded to physicians from the University of Bern and the Inselspital, University Hospital Bern.

28 Jan 2021

New approach to capture natural killer cells and harvest cancer-killing packets

Building on the promise of emerging therapies to deploy the body's "natural killer" immune cells to fight cancer, researchers at the University of Michigan Rogel Cancer Center and U-M College of Engineering have gone one step further.

28 Jan 2021

Fetal and neonatal therapy combination may lessen the aftereffects of congenital CMV infection

A cross-institutional research group has revealed for the first time in the world that infants with symptomatic congenital cytomegalovirus (CMV) infection who were treated with a combination of immunoglobulin fetal therapy and neonatal therapy with antiviral drugs were less likely to experience the severe aftereffects associated with the infection than those who only received the neonatal therapy.

28 Jan 2021

Variants emerging during COVID-19 pandemic resist antibody neutralization

Researchers in the U.S. have warned that recently emerged variants of SARS-CoV-2 have become worryingly resistant to monoclonal antibody therapies, plasma from convalescent patients and sera from vaccinated individuals.

28 Jan 2021

Can the US keep covid variants in check? Here’s what it takes

The covid-19 variants that have emerged in the United Kingdom, Brazil, South Africa and now Southern California are eliciting two notably distinct responses from U.S. public health officials.

28 Jan 2021

Moderna vaccine shows robust suppression of SARS-CoV-2 infection in animal model

Researchers have demonstrated that the prime or prime-boost vaccination of Moderna vaccine in hamsters induced robust neutralizing antibodies, ameliorated weight loss, and suppressed SARS-CoV-2 replication in the airways.

28 Jan 2021

Melatonin synthesized in the lungs acts as a barrier against SARS-CoV-2

Melatonin synthesized in the lungs acts as a barrier against SARS-CoV-2, preventing expression of genes that encode proteins in cells such as resident macrophages in the nose and pulmonary alveoli, and epithelial cells lining the alveoli, all of which are entry points for the virus.

28 Jan 2021

Ebola survivors experienced a resurgence in antibody levels after recovery

A high proportion of survivors of Ebola experienced a resurgence in antibody levels nearly a year after recovery, a new University of Liverpool study has found.

27 Jan 2021